



(51) International Patent Classification:

C07K 14/705 (2006.01) G01N 33/53 (2006.01)
C07K 16/28 (2006.01) G01N 33/543 (2006.01)
C07K 16/42 (2006.01) G01N 33/68 (2006.01)

(21) International Application Number:

PCT/US2023/072710

(22) International Filing Date:

23 August 2023 (23.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/373,426 24 August 2022 (24.08.2022) US

(71) Applicant: **AMGEN INC.** [US/US]; c/o Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California
91320-1799 (US).

(72) Inventors: **MILLER, Mieke J.**; c/o Amgen Inc., One Am-
gen Center Drive, Thousand Oaks, California 91320-1799
(US). **KING, Chadwick**; c/o Amgen Inc., One Am-
gen Center Drive, Thousand Oaks, California 91320-1799
(US). **KROENKE, Mark**; c/o Amgen Inc., One Am-
gen Center Drive, Thousand Oaks, California 91320-1799
(US). **STARCEVIC MANNING, Marta**; c/o Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California
91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-DRUG ANTIBODY ASSAYS



(57) Abstract: The present invention relates methods of detecting anti-drug antibodies and kits for using such assays.